Over my career in scientific writing and editing, I’ve found many helpful lists, tips, and resources that I’ve gathered here for your reference.
At the 2014 AAAS meeting, Barbara Gastel presented “Editing Your Own Papers and Proposals: How to Wow Reviewers and Aid Readers.” See the handout [pdf] from this session that includes editing checklists.
Here’s an editing checklist [pdf] from Grammar Girl that comes in handy when writing or editing your own work.
Ten writing tips for ESL academic authors from Text and Academic Authors.
“Rookie Mistakes That Even Veterans Make” [pdf] was presented by Bill Walsh of The Washington Post at the American Copy Editors Society meeting in 2014.
Last but not least, see what happens when medical writing and editing go wrong with the Dizzy Awards 2012.
The US Food and Drug Administration (FDA) provides guidance to pharmaceutical and medical device manufacturers about distributing information on unapproved uses of their products. In 2009, the FDA released what is commonly referred to as “Good Reprint Practices.“* The FDA recognized that off-label or unapproved uses could be important to the standard of clinical care and to health care providers knowledge.
The guidelines were meant to outline how this information should be disseminated, through what types of publications, and how the information should be qualified. The ultimate goal was to allow companies to share scientific research about unapproved uses without promoting these uses. Continue reading How drug and device companies should distribute scientific literature about unapproved uses